FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...

Hello Health Rounds Readers! Today we highlight research findings reported at ESMO 2024, the annual meeting of the European ...